EX-99.1 2 ea120432ex99-1_neuroone.htm INVESTOR PRESENTATION DATED APRIL 2020

Exhibit 99.1

NeuroOne™ Medical Technologies Corporation Company Overview High - definition, minimally invasive platform electrode technology for recording & treatment of neurological disorders such as epilepsy, Parkinson’s Disease and Failed Back Surgery Syndrome

FORWARD LOOKING STATEMENT S 2 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION This presentation includes forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward - looking statements. In some cases, you can identify forward looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward looking statements may include statements regarding the Company’s business strategy, the Company’s estimated revenues and revenue growth, the potential uplisting of the Company’s stock to an exchange , existing or future market size, market demand, potential growth opportunities, the continuation of existing partnerships, the existence and strength of competition for the Company’s technology, additional applications of the Company’s technology, capital requirements, the potential receipt of DARPA or NIH grants, costs and risks related to the technology, anticipated advantages of the technology, the strength and growth of the Company’s intellectual property portfolio, anticipated outcome of ongoing litigation, the timing of product development, the timing and results of clinical trials, the timing of regulatory submissions, the length of review of the Company’s 510(k) submissions, the timing or occurrence of regulatory clearance or approvals, and the timing and success of commercialization of the Company’s products . Although the Company believes that we have a reasonable basis for each forward - looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. These forward looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the SEC. These forward looking s tat ements speak only as of the date of this presentation and the Company undertakes no obligation to revise or update any forward looking statements for any reason, even if new information becomes available in the future. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market share and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products. Caution: Federal law restricts this device to sale by or on the order of a physician

COMPANY OVERVIEW Next generation electrode technology company specializing in development and commercialization of hi - definition thin film electrodes for the diagnosis and treatment of various neurological conditions such as epilepsy, Parkinson’s Disease and chronic pain due to failed back surgery syndrome • First FDA 510(k) clearance for cortical electrode product family December 2019 • Ability to perform recording, ablation and stimulation with the same electrode Minimally invasive flexible patented technology leverages printed circuit technology • We expect our technology could reduce manufacturing costs, procedural costs and improve patient outcomes • Mayo Clinic assisted in the development process, successfully used devices in humans as part of a research protocol an d currently maintains an ownership position in the Company • Well positioned electrode technology has strong potential for future use in spinal cord stimulation and artificial intelligence applications, which may play an important future role in treating patients with more complex neurological issues Experienced Management Team, Board of Directors and two Advisory Boards with highly acclaimed physicians from prestigious institutions Strong and g rowing patent portfolio 3 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION

PRODUCT SUMMARY Evo™ Cortical Electrode Status A portfolio of hi - definition strip and grid thin film electrodes for recording brain activity - includes disposable cable assemb ly 510(k) received Evo™ sEEG Depth Electrode Status A portfolio of hi - definition depth thin film electrodes used for recording brain activity - includes disposable cable assembly In late development Ablation Electrode Status A system which is comprised of an sEEG electrode (developed by the Company), commercially available fiber optic temperature probe and RF generator. The potential benefits of RF ablation include: more precise lesions, same electrode used for recording and ablation, reduction in number of patient procedures. In development; Performed feasibility testing Deep Brain Stimulation Status A deep brain electrode that may allow “directional” stimulation, increasing the precision of the stimulation target. The electrode would connect to a permanently implanted commercially available deep brain stimulator. Concept phase Spinal Cord Stimulation Status The potential to place paddle electrodes minimally invasively versus the current invasive method of a surgical incision and include additional contacts than currently commercially available to provide greater precision . The paddle electrodes will connect to a commercially available spinal cord stimulator. In development; Concept phase

DIRE NEED FOR IMPROVED ELECTRODE TECHNOLOGY Despite large advances in therapeutics and surgical options over the last few decades, one area that has not seen significant improvement is electrode technology for neurological disorders . These disorders include epilepsy, Parkinson’s disease, essential tremors, dystonia , chronic back pain and more . Most companies with current technologies are focused on software and hardware and have neglected electrode improvements. Current US commercially approved electrode technologies are limited in resolution, making it more challenging to assess problematic tissue, present the inability to place minimally invasively, require multiple surgeries, utilize technology from the 1960’s, rely on manual labor, are associated with high manufacturing costs and frequent backorders. No US commercially approved electrodes have the scalability for artificial intelligence medical applications. 5 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION

What physicians want in new electrode technology 6 Less Invasive Surgeries • Reduced number of surgeries for diagnosis and treatment • Minimally invasive procedures • Reduced brain inflammation Improve surgical outcomes • Decreased procedure time • Ability to be more precise in targeting tissue for ablation and stimulation • Customized electrodes based upon patient need • Short lead times to receive products Better Mapping Technology • Potential for lower impedance recordings • Capable of high definition recordings • High confidence in identifying seizure focus

7 BRAIN ELECTRODE MARKET OVERVIEW Epilepsy Market Prevalence 1 Epilepsy Surgery Market Potential 1 Brain Tumor IOM Market Potential (cortical only) 1 700,000 Surgical Candidates 7 Million Electrodes a ~$5 Billion Revenue Potential b 240,000 Surgical Candidates 480,000 Electrodes c ~ $240 Million Revenue Potential d 3.4 Million People with Epilepsy 1 Million People with refractory epilepsy 700,000 People are surgical candidates Brain Tumor IOM Market Prevalence 1 Quick Facts: Current Value for the Brain Electrode Market $140M 2 CAGR = 4.5% 2 (2016 – 2025) NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION a) 10 electrodes per surgery b) ASP of $750 c) 2 electrodes per surgery d) ASP of $500 350,000 People have a brain tumor 240,000 People are surgical candidates 1. Noaeill, L.. (2020). NeuroOne Market Research. Unpublished data on file. 2. Brandessence Market Research. (2019). Subdural Electrode Market. Unpublished data on file.

EVO™ CORTICAL ELECTRODE Thin Film Design Disposable Cables Clinical Evidence Greater Precision The thin film, flexible design provides new options for surgical placement. Single thin tail has less bulk while tunneling through the scalp and less incisions for possible infections. Eliminates the need to sterilize cables saves the surgical staff time, allowing them to focus on other important tasks. Disposable cables saves the hospital resources by not having staff manage the sterilization of electrode cables. Study conducted by the Mayo Clinic found our electrodes created less tissue inflammation on the brain after being implanted for 7 days. 1 1. Bower R, et al. December 2017. Development of Polyimide electrodes for high - resolution intracranial EEG recordings. ( Abst . 1.060) American Epilepsy Society. Washington, D.C. Able to customize contact size and shape on electrodes per neurosurgeon’s request. The single substrate allows for lower impedance to improve signal quality. Less Bulk Less Management Less Inflammation More Control Applications: Epilepsy surgery and intraoperative mapping Competitors: Ad - Tech, PMT, Integra, Cortec 8 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION

THIN - FILM DEPTH ELECTRODE 9 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION Applications: Epilepsy surgery and awake brain mapping procedures Competitors: Ad - Tech, PMT, Integra, DIXI NeuroOne Advantages: Increase signal clarity / reduced noise Better tactile feedback during insertion into brain tissue MR Safe Faster order fulfillment due to manufacturing process

COMBINATION DIAGNOSTIC + ABLATION DEPTH ELECTRODE FOR EPILEPSY NeuroOne Advantages vs Current Laser Technology : One procedure for diagnostic and therapeutic expected to save time, money and potentially improve d patient outcomes May provide bedside treatment capability saving significant time and cost Uses well established RF energy to ablate tissue Overcomes inherent laser drawbacks such as heat dissipation Relationship with Dr. Jorge Gonzalez, a pioneer in epilepsy surgery 10 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION Applications: Remove brain tumors and lesions causing seizures Competitors: Medtronic and Monterris Medical Fiber Optic Temperature Probe (offered by 3 rd party vendors) RF Generator (offered by 3 rd party vendors) + + NeuroOne sEEG Electrode

DEEP BRAIN STIMULATION SYSTEM NeuroOne Advantages: Utilizes sEEG depth electrode design Our high definition electrodes have been shown to detect micro seizures 1 which may improv e responsive stimulation a lgorithms Additional technology applications may be suitable for drug delivery 11 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION Applications: Parkinson’s Disease, epilepsy, essential tremors Competitors: NeuroPace , Medtronic, Boston Scientific, Abbot/SJM Currently a $500M market with potential of $6B 1. Bower R, et al. December 2017. Development of Polyimide electrodes for high - resolution intracranial EEG recordings. ( Abst . 1.060) American Epilepsy Society. Washington, D.C.

SPINAL CORD STIMULATION MARKET OVERVIEW Market breakdown by diagnosis Global Market Growth Implant Procedure Locations NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION 12 Infinium Global Research. (2018). Spinal Cord Stimulation Market. Unpublished data on file. Failed Back Surgery Syndrome Complex Regional Pain Syndrome Ischemic Limb Pain Others Largest Market at a 7.6% CAGR between 2017 and 2024

SPINAL CORD STIMULATION SYSTEM NeuroOne Advantages: Ability to place permanent electrodes percutaneously Expandable midsection allows electrode to extend without displacement “Scalability” of electrodes offer greater precision of targeted stimulation area Design allows for use for trial period and permanent placement thereby reducing two procedures to one 13 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION Competitive solutions include paddle and cylinder electrodes which are placed via two different procedures. Major vendors in this market include: Medtronic, Boston Scientific, Abbott NeuroOne’s solution includes a paddle implanted like a cylinder electrode so only one procedure is needed to implant the electrode.

BRIDGING THE GAP – ARTIFICIAL INTELLIGENCE (A.I.) Damaged neurons can cause a break in neuron to neuron connectivity: etiology for many neurological disorders Successful treatments achieved by implanting small wires to record and reintroduce the natural signal back Elon Musk and others have started companies to try to implant millions of wires in the brain NeuroOne’s high - definition thin film platform could allow for recording and stimulation of the neurons to bridge these gaps more effectively NeuroOne technology is scalable allowing thousands of contacts to be implanted NeuroOne Advisory Board of 7 leading A.I. thought leaders established 14 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION

NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION 15 TARGET PRODUCT DEVELOPMENT TIMELINE¹ Cortical Electrode Product Testing 510k Launch Diagnostic Depth Electrode Product Development Product Testing 510k Launch Dx + Ablation Depth Electrode Product Development Product Testing 510k + data Launch MI Cortical Electrode Product Development – applied for SBIR Grant in February 2018 Product Testing 510k Launch Calendar year Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 Product Development Product Testing 510k + data Launch Spinal Cord Stimulation Electrode 15 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION ˂ -------------- Achieved Milestones ------------ ˃ ˂ ------------------ Targeted Milestones ---------------------- ˃ ¹These targets are subject to a number of risks, uncertainties and assumptions, described further in “Forward Looking Statements” on page 2 of this presentation.

INTELLECTUAL PROPERTY TO DATE 16 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION In - Licensed Patents From WARF At UW - Madison Patent No. Issue Date Title Abstract Summary Other Information to discuss US 8,483,794 July 2013 Method for implanting an electrode that unfurls in response to a predetermined stimulus Method of placing diagnostic film used for long - term stimulation and recording via a minimally invasive approach Company and its patent counsel are planning new filings to update these cases. Per university patent filing protocol, foreign filings were not made on a timely basis, prior to NMTC obtaining these patent rights. US 8,386,007 Feb 2013 Thin - film micro electrode array and method Method and design for a long - term flexible electrode array for recording and stimulating on the cortex utilizing a minimally invasive approach Company and its patent counsel are planning new filings to update these cases. Per university patent filing protocol, foreign filings were not made on a timely basis, prior to NMTC obtaining these patent rights. US 7,774,053 Aug 2010 Neural probe array Design and spacing of an array of electrodes for subdural implantation capable of drug delivery through the apertures Company and its patent counsel are planning new filings to update these cases. Per university patent filing protocol, foreign filings were not made on a timely basis, prior to NMTC obtaining these patent rights. Freedom to Operate ( FTO ) Opinion Completed August 2018 – cleared to commercialize US Provisional Applications Filing Date Title Abstract Summary Other Information Mar 2017 Improved Neural Probe Systems, Methods and Devices Intentionally not disclosed US & International patent application filed 4/2/2018; Patent published 10/11/18 O ct 2017 Improved Neural Probe Systems, Methods and Devices Intentionally not disclosed US & International patent filed 4/2/2018; Patent published 10/11/18 Mar - 19 Agent Delivering Neural Probe Devices and Related Methods Intentionally not disclosed Jul - 19 Minimally Invasive Electrode and Delivery Device and Methods Intentionally not disclosed Aug - 19 Spinal Cord Stimulation Systems, Method and Delivery Intentionally not disclosed

SCIENTIFIC ADVISORY BOARD Greg Worrell MD, PhD, Chairman of the Scientific Advisory Board World renowned neurologist at Mayo Clinic. Recognized by the American Epilepsy Society (AES), the American Academy of Neurology (AAN), the American Neurological Association (ANA), and the Citizens United in Research for Epilepsy (CURE) Foundation for his contributions to the field of epilepsy research. Dr. Worrell is a frequent keynote speaker at neurology conferences and has published 90 papers. Jamie Van Gompel, MD Neurosurgeon practicing at Mayo Clinic, specializing in epilepsy surgery utilizing minimally invasive techniques. Since 2008, Dr. Van Gompel has authored or co - authored 87 papers on clinical outcome projects centered on neurological conditions. Dr. Van Gompel works collaboratively with colleagues from Mayo Clinic’s Epilepsy and Neurophysiology lab, engaging in clinical work relative to brain stimulation as a viable restorative therapy for epilepsy over current treatment methodologies. Jorge Gonzalez, MD, PhD Neurosurgeon practicing at The University of Pittsburgh , specializing in minimally invasive surgical techniques to treat epilepsy. Dr. Gonzalez has authored or contributed to almost 200 publications. Dr. Gonzalez holds broad experience in the treatment and services of epilepsy surgery in multiple patient populations and clinical trials involving neurosurgery. Greg Esper, MD, MBA Associate Professor, Vice - President of Clinical Affairs, and Director of New Care Models in the Neurology Department at Emory University. Vice Chair of the Medical Economics and Management Committee for the American Academy of Neurology (AAN). Dr. Esper was Chair of the Navigating Health Reform Task Force for the AAN in 2012. Justin Williams, PhD Department Chair and Vilas Distinguished Achievement Professor at University of Wisconsin. Dr. Williams is credited with multiple publications, patents, and research in the field of thin - film electrodes for neurological recording, ablation, and stimulation. Additional physicians from Boston Children's, UCLA, Stanford and Emory have also joined the advisory board. 17 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION

COMPANY MANAGE MENT Dave Rosa, President and Chief Executive Officer An entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, has served on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University, and a BS in Commerce and Engineering from Drexel University . Mark Christianson, Vice President of Business Development In excess of 15 years of executive sales, sales management, marketing, and project management experience with development stage companies. Prior to NeuroOne, Mr. Christianson held the positions of North American Sales Manager for Cortec Corporation, a manufacturer of specialty chemical products, and Regional Sales Manager for PMT Corporation, a leading manufacturer of products for neurosurgery, orthopedics and plastic surgery. He holds an accounting degree from Augsburg College. 18 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION Steve Mertens, Chief Technology Officer Prior to joining NeuroOne, Mr. Mertens was Sr. Vice President of R&D and Operations at Nuvaira, a privately held lung denervation company developing minimally invasive products for obstructive lung diseases. Before that, he was a Senior Vice President of Research and Development for Boston Scientific, where he guided a wide range of technologies through product development for the cardiology, electrophysiology, and peripheral vascular markets. Mr. Mertens holds a Bachelor of Science degree in Chemical Engineering from the University of Minnesota and a master’s degree in Business Administration from the University of St. Thomas. Leah Noaeill, Senior Director of Marketing Mrs. Noaeill comes to NeuroOne with fifteen years in medical device marketing in a connected healthcare environment. Most recently, she worked at Smiths Medical leading the Infusion Software marketing and application support teams. Prior to Smiths Medical, Mrs. Noaeill worked at Hill - Rom, managing their Respiratory Care device portfolio. She led the development and launch of the company’s first mobile airway clearance vest, encompassing product definition, key opinion leader engagement, clinical claims, sales initiatives, and marketing. Prior to Hill - Rom, Mrs. Noaeill worked at Medtronic where she led marketing efforts for their Connected Care portfolio and implantable cardiac devices.

BOARD OF DIRECTORS Paul Buckman, Chairman of the Board Mr. Buckman is currently the President of North America of LivaNova PLC, a London - based medical device manufacturer, publicly trading on the N asdaq . The Company develops devices used for cardiac surgery, neuromodulation, and cardiac rhythm management. LivaNova was formed by a 2015 $2.7 billion merger between Ho ust on, Texas - based Cyberonics, Inc., and Milan, Italy - based Sorin S.p.a. Mr. Buckman has been a co - founder, president, or CEO of several medical device companies. He has led many of these companies to successful exits. He is currently on the board of several public and private medical device firms. Mr. Buckman received a Master’s degree in Business Administration and Finance and a BA degree in Business Administration from Western Michigan University. Dave Rosa, President and Chief Executive Officer An entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, has served on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University, and a BS in Commerce and Engineering from Drexel University. Jeffrey Mathiesen Mr. Mathiesen is currently the Chief Financial Officer of Gemphire Therapeutics Inc., a publicly - held clinical - stage biopharmaceutical company. He has held executive positions with publicly - traded and privately - held companies dating back to 1993, including vice president and chief financial officer positions. Mr. Mat hiesen also serves as a Director, Audit Committee Chairman and Nominating and Governance Committee Member of Sun BioPharma, Inc., a publicly - traded clinical - stage biopharmaceutical company. H e received a B.S. in Accounting from the University of South Dakota and is a Certified Public Accountant. Edward Andrle Mr. Andrle most recently served as the General Manager of the Neuromodulation franchise at LivaNova PLC. Prior to LivaNova , Mr. Andrle served as Sorin’s Vice - President of Strategy & Business Development. He also has previously held executive positions with Boston Scientific and Baxter, leading large produc t p ortfolios in both neuromodulation and cardiac devices. Mr. Andrle has been a co - founder and CEO for several early stage medical device companies in both the neuromodulation and cardiovasc ular industries. In addition, he has also served on the board of many privately held medical device companies. Mr. Andrle received his MBA from Stanford Graduate School of Business and his B.S. in Chemical Engineering from the University of Notre Dame. 19 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION

SELECT FINANCIAL INFORMATION Listed on OTCQB: NMTC Financial Data 1 Price: $ 2.33 90 - Day Price Range: $ 1.83 - $ 3.73 Daily Volume – Last 30 Day Average: 9,737 Market Capitalization: $ 32.3 M illion Shares Outstanding: 13.9 Million Shares in Float ~ 6.3 Million Convertible Notes – Due May 1, 2020 : $3.2 Million 20 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION ¹ As of February 11, 20 20

2020 CORPORATE GOALS Expected FDA 510(k) submission for 2 nd product First commercial sale for human use Uplist to exchange Conclusion of PMT litigation Secure at least one DARPA or NIH grant for new technologies 21 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION

INVESTMENT HIGHLIGHTS Substantial m arket opportunity Disruptive, patented technologies • Address a significant and unmet need • E xpectation – substantially improved outcomes • Meet the need to lower costs • Established reimbursement Majority of NeuroOne’s products expect U.S. FDA 510(k) process Platform technology potential for multiple applications: • Diagnostic and therapeutic capabilities • Brain related disorders, spinal cord stimulation, AI Mayo and Cleveland Clinic ha ve successfully used devices in humans or animals Experienced management team, Advisory Board s , and Board of Directors First FDA product clearance Q4 2019 with second 510(k) submission anticipated in 2020 Growing patent portfolio 22 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION

C ON T A C T Dave Rosa President and Chief Executive Officer Email: daver@n1mtc.com 23 NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION